Cargando…
Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
HIV latency in resting CD4+ T cell represents a key barrier preventing cure of the infection with antiretroviral drugs alone. Latency reversing agents (LRAs) can activate HIV expression in latently infected cells, potentially leading to their elimination through virus-mediated cytopathic effects, ho...
Autores principales: | Marsden, Matthew D., Wu, Xiaomeng, Navab, Sara M., Loy, Brian A., Schrier, Adam J., DeChristopher, Brian A., Shimizu, Akira J., Hardman, Clayton T., Ho, Stephen, Ramirez, Christina M., Wender, Paul A., Zack, Jerome A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academic Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018613/ https://www.ncbi.nlm.nih.gov/pubmed/29800728 http://dx.doi.org/10.1016/j.virol.2018.05.006 |
Ejemplares similares
-
Designed, Synthetically Accessible Bryostatin Analogues Potently Induce Activation of Latent HIV Reservoirs in vitro
por: DeChristopher, Brian A., et al.
Publicado: (2012) -
In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication
por: Marsden, Matthew D., et al.
Publicado: (2017) -
“Picolog,” a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYC-Induced Lymphoma In Vivo
por: DeChristopher, Brian A., et al.
Publicado: (2012) -
Simplified Bryostatin Analogues Protect Cells from
Chikungunya Virus-Induced Cell Death
por: Staveness, Daryl, et al.
Publicado: (2016) -
Tracking HIV Rebound following Latency Reversal Using Barcoded HIV
por: Marsden, Matthew D., et al.
Publicado: (2020)